Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer

A Krarup-Hansen; E Andersen; K Elbaek; S N Rasmussen; M Dalmark

Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer

A Krarup-Hansen, E Andersen, K Elbaek, S N Rasmussen, M Dalmark

Kræftbehandling

4 Citationer (Scopus)

Abstract

In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.

Originalsprog	Engelsk
Tidsskrift	Acta oncologica
Vol/bind	27
Udgave nummer	5
Sider (fra-til)	521-5
Antal sider	5
ISSN	0284-186X
Status	Udgivet - 1988

Citationsformater

@article{c6afd6288d9341bd9a04b8d312986ffa,

title = "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer",

abstract = "In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.",

keywords = "Administration, Oral, Adult, Aged, Drug Evaluation, Female, Humans, Idarubicin, Male, Middle Aged, Neoplasms",

author = "A Krarup-Hansen and E Andersen and K Elbaek and Rasmussen, {S N} and M Dalmark",

year = "1988",

language = "English",

volume = "27",

pages = "521--5",

journal = "Acta oncologica ",

issn = "0284-186X",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer

AU - Krarup-Hansen, A

AU - Andersen, E

AU - Elbaek, K

AU - Rasmussen, S N

AU - Dalmark, M

PY - 1988

Y1 - 1988

N2 - In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.

AB - In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.

KW - Administration, Oral

KW - Adult

KW - Aged

KW - Drug Evaluation

KW - Female

KW - Humans

KW - Idarubicin

KW - Male

KW - Middle Aged

KW - Neoplasms

M3 - Journal article

C2 - 3203009

SN - 0284-186X

VL - 27

SP - 521

EP - 525

JO - Acta oncologica

JF - Acta oncologica

IS - 5

ER -

Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer

Abstract

Fingeraftryk

Citationsformater